Overview

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections. The study will also characterize the safety and tolerability of treatment with ceftobiprole medocaril in patients with complicated skin and skin structure infections.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Basilea Pharmaceutica
Treatments:
Ceftazidime
Ceftobiprole
Ceftobiprole medocaril
Cephalosporins
Vancomycin
Criteria
Inclusion Criteria:

- Diagnosis of an infection consistent with complicated skin and skin structure
infections.

Exclusion Criteria:

- Known or suspected hypersensitivity to any study medication or other related
anti-infective medication

- Any known or suspected condition or concurrent treatment contraindicated by the
prescribing information

- Previous enrollment in this study

- Treatment with any investigational drug within 30 days before enrollment